Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
____________________
FORM
8K/A
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
____________________
Date
of
Report
December
5, 2007
Date
of
Original Report
October
10, 2007
_______________________
Nanobac
Pharmaceuticals, Incorporated
(Exact
name of registrant as specified in its charter)
|
Florida
(State
or Other Jurisdiction
of Incorporation)
|
|
0-24696
(Commission
File Number)
|
|
59-3248917
(I.R.S.
Employer
Identification Number)
|
4730
N Habana Ave Suite 205 Tampa FL 33614
(Address
of Principal Executive Office) (Zip Code)
(813)
264-2241
(Registrant’s
telephone number, including area code)
Item
4.01 Changes in Registrant's Certifying Accountant.
(a)
On
October 2, 2007, the Company received written notification from its independent
registered public accountants, Aidman, Piser & Company, P.A. ("Aidman
Piser") that they had resigned as the Company's auditors
The
reports of Aidman Piser on the Company's financial statements for the past
two
fiscal years, did not contain an adverse opinion or a disclaimer of opinion
and
were not qualified or modified as to uncertainty, audit scope, or accounting
principles, except that substantial doubt was raised as to the Company's ability
to continue as a going concern.
In
connection with the audits of the Company's financial statements for the each
of
the two fiscal years ended December 31, 2006 and 2005, and in the subsequent
interim periods, January 1 2007 through October 2, 2007, there were no
disagreements with Aidman Piser on any matters of accounting principles or
practices, financial statement disclosure, or auditing scope and procedures
which, if not resolved to the satisfaction of Aidman Piser, would have caused
Aidman Piser to make reference to the matter in their report.
The
Company has requested Aidman Piser to furnish it with a letter addressed to
the
Commission stating whether it agrees with the above statements which the Company
will file as an exhibit in this form upon its receipt. This amendment furnishes
the letter from Aidman Piser as Exhibit 16 acknowledging agreement through
this
current December 5, 2007 8-K/A filing.
Item
9.01 Financial Statements and Exhibits
(c)
Exhibits
16
-
Letter from Aidman, Piser & Company, P.A.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
| |
|
|
| |
Nanobac Pharmaceuticals Incorporated.
(Registrant)
|
|
|
|
| Date:
December 5, 2007 |
By: |
/s/
John
D. Stanton |
| |
John
D. Stanton, Chief Executive Officer |
| |
|